MedTrace Logo

Health-related Quality of Life, Psychological Distress and Fatigue in Metastatic CRPC Patients Treated With Radium-223

NCT04995614 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 122

Last updated 2021-08-09

No results posted yet for this study

Summary

The aim of the current prospective multicenter study is to evaluate cancer-specific and bone metastases related HR-QoL, psychological distress and fatigue in mCRPC patients before, during and after treatment with radium-223 in daily practice. Furthermore, the investigators aim to determine patient groups with identical health-related quality of life patterns over time, in order to identify variables related to health-related quality of life deterioration during the course of treatment, as patients with health-related quality of life deterioration may need specific attention to preserve health-related quality of life.

Conditions

Interventions

DRUG

Radium-223

Prospective observational cohort study investigating patient-reported outcomes

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Inge M. van Oort, MD, PhD · Radboud University Medical Center

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2020-06-29
Completion
2020-06-29

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04995614 on ClinicalTrials.gov